Exploring Peyer’s Patch Uptake as a Strategy for Targeted Lung Delivery of Polymeric Rifampicin Nanoparticles

Abstract

Uptake of nanoparticles through Peyer's Patches following oral administration could enable translocation through lymph to lymphatic organs like the lungs. An important consideration, however, is nanosize and particle hydrophobicity. Furthermore, as delivering the nanoparticles to the intestine where the Peyer's Patches are localized is important, their intact and rapid transit through the stomach into the intestine is highly desirable. We report hydrophobization of mucoadhesive Rifampicin-GantrezAN-119 nanoparticles (GzNP) using a hydrophobic polymer, ethyl cellulose (EC), with the objectives of augmenting Peyer's Patch uptake due to enhanced hydrophobicity and increased intestinal localization as a result of decreased mucoadhesion. RIF-Gantrez-EC nanoparticles (ECGzNP2) exhibited >13% RIF loading and an average particle size of 400-450 nm, which is appropriate for translation through lymph following Peyer's Patch uptake. Higher contact angle (67.3 ± 3.5° vs 30.3 ± 2.1°) and lower mucoadhesion (30.7 ± 4.8 g vs 87.0 ± 3.0 g) of ECGzNP2 over GzNP confirmed hydrophobization and lower mucoadhesion. Fluorescence photomicrographs of intraduodenally administered coumarin-labeled RIF-NP in rats demonstrated higher Peyer's Patch uptake with ECGzNP2, while the increased lung/plasma RIF ratio signified lymph mediated lung targeting. The gastrointestinal transit study in rats, which revealed a significantly higher intestine-to-stomach accumulation ratio with ECGzNP2 (3.4) compared to GzNP (1.0) [ p < 0.05], confirmed availability of the NP in the intestine for Peyer's Patch uptake. Such uptake enabled 182.4 ± 22.6% increase in relative bioavailability, a ∼2-fold higher plasma AUC/MIC ratio and significantly higher lung concentration with ECGzNP2, thereby proposing better efficacy. A significantly higher lung/liver ratio with ECGzNP2 also suggested lower hepatic exposure. The repeated dose 28-day oral toxicity study demonstrated the safety of the nanocarrier and reduced hepatotoxicity with ECGzNP2 compared to RIF. We hereby demonstrate uptake of orally administered NP through Peyer's Patches as a feasible strategy for lung targeting.

A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19

“…Hence considering strategies to enhance bioavailability could be an important approach to enhance efficacy at possibly lower doses ( Omolo et al, 2020 ). Furthermore, directing the drug in high concentration to the target site following oral administration could be achieved by lymphatic targeting of oral particulate carriers ( Bachhav et al, 2018 , 2017 ). With the myriad targets the drug exhibits potential to attack in the pathogenesis of COVID-19, let us hope it is the panacea the world seeks to overcome the fatality and the fear of COVID-19.…”

Polymeric curcumin nanoparticles by a facile in situ method for macrophage targeted delivery

“…However, at pH 6.8 sustained release of CUR from ISCurNP was observed upto 24 hr with maximum 46.6% release while free CUR demonstrated of 28.09% release (Supporting Information Figure S6). We have previously observed that hydrophilic NPs show gastric tropism while hydrophobic NPs favor intestinal accumulation. Such intestinal accumulation could favor high uptake of intact NPs through M cells of Peyer's patches followed by translocation through the lymph into systemic circulation .…”

<p>Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy</p>

“…119,120 The gastrointestinal localization and paracellular or lymphoid transport can be improved by adjusting the molecular weight, hydrophobicity, and adhesion of polymers. 121,122 As a natural cationic polysaccharide, chitosan (CS) has been used for the delivery of small molecules, proteins, polypeptides, polysaccharides, and genes. [123][124][125] At the same time, many chitosan derivatives with better delivery properties have been developed such as trimethyl chitosan, carboxymethyl chitosan, and thiolated chitosan, all of which played an important role in the development of oral drug delivery systems.…”

“…As a result, the relative bioavailability of rifampicin-Gantrez-ethylcellulose nanoparticles nearly tripled, and more drugs accumulated in lung. 122 Helicobacter pylori is a micro-aerobic gram-negative bacterium that colonizes the deep layer of human gastric mucus with acidic pH values. 135,136 Therefore, therapeutic agents not only need to penetrate the gastric mucus layer but also need to be protected from the acidic environment.…”